摘要
目的:观察益气扶正养阴化痰法验方联合酪氨酸激酶抑制剂(TKIs)治疗Ⅲa~Ⅳ期表皮生长因子受体(EGFR)突变型非小细胞肺癌对延缓TKIs耐药及患者生存质量的影响。方法:回顾性分析2016年1月至2019年1月在泉州市中医院诊断为Ⅲa~Ⅳ期EGFR突变型非小细胞肺癌的80例病例,根据治疗方案不同归为对照组和观察组,各40例。对照组患者采用单纯给予EGFR-TKIs治疗,观察组患者在对照组基础上联合益气扶正养阴化痰法验方治疗,记录两组患者的生存质量,安全性,近期疗效和疾病进展时间。结果:治疗后观察组患者生活质量改善明显优于对照组,差异具有统计学意义(P<0.05)。治疗期间两组患者均未发生Ⅲ级以上的皮疹和腹泻。观察组患者皮疹发生率为75.00%,与对照组的77.50%比较,差异无统计学意义(P>0.05);观察组患者腹泻发生率为52.5%,与对照组的55.00%比较,差异无统计学意义(P>0.05)。观察组患者的疾病控制率(DCR)为82.50%,高于对照组的70.00%,差异具有统计学意义(P<0.05)。对照组患者中位疾病进展时间为11.5月,观察组为15.0月,延缓TKIs耐药3.5月。经Logrank检验,差异具有统计学意义(P<0.05)。结论:益气扶正养阴化痰法验方联合TKIs治疗Ⅲa~Ⅳ期EGFR突变型非小细胞肺癌可明显改善患者生存质量,延缓患者耐药,提高生存质量。
Objective To observe the effect of Yiqi Fuzheng Yangyin Huatan prescription combined with tyrosine kinase inhibitors(TKIs)on delaying TKIs resistance and quality of life of patients with epidermal growth factor receptor(EGFR)mutant non-small cell lung cancer in stageⅢa~Ⅳ.Methods A retrospective analysis was performed on 80 patients diagnosed with stageⅢa~ⅣEGFR mutant non-small cell lung cancer in Quanzhou Hospital of Traditional Chinese Medicine from January 2016 to January 2019,who were divided into a control group and an observation group according to different treatment regimen,with 40 cases in each group.Patients in the control group were treated with EGFR-TKIs alone,and patients in the observation group were treated with Yiqi Fuzheng Yangyin Huatan prescription on the basis of the control group.The quality of life,safety,short-term efficacy and time of disease progression of patients in the two groups were recorded.Results After treatment,the quality of life in the observation group was significantly better than that in the control group,and the difference was statistically significant(P<0.05).No rash and diarrhea above gradeⅢoccurred in the two groups during treatment.The incidence of rash in the observation group was 75.00%(30/40),which was not statistically significant compared with 77.50%in the control group(P>0.05).The incidence of diarrhea in the observation group was 52.5%,which was not statistically significant compared with 55.00%in the control group(P>0.05).The disease control rate(DCR)of the observation group was 82.50%,higher than that of the control group(70.00%),and the difference was statistically significant(P<0.05).The median time to disease progression was 11.5 months in the control group,15.0 months in the observation group,and 3.5 months of delayed TKIs resistance.Logrank test showed that the difference was statistically significant(P<0.05).Conclusion Yiqi Fuzheng Yangyin Huatan prescription combined with TKIs in the treatment of stageⅢa~ⅣEGFR mutant non-small cell lung cancer can significantly improve the quality of life of patients,delay drug resistance and improve survival benefits.
作者
陈劲智
刘玉
郑琴珠
CHEN Jin-zhi;LIU Yu;ZHENG Qin-zhu(Quanzhou Hospital of Traditional Chinese Medicine,Fujian Quanzhou 362000;Quanzhou Institute of Medicine,Fujian Quanzhou 362000;Quanxiu Street Community Health Service Center,Fengze District,Quanzhou City,Fujian Quanzhou 362000)
出处
《深圳中西医结合杂志》
2023年第8期14-17,共4页
Shenzhen Journal of Integrated Traditional Chinese and Western Medicine
关键词
表皮生长因子受体突变型非小细胞肺癌
益气扶正养阴化痰法
酪氨酸激酶抑制剂
酪氨酸激酶抑制剂耐药
Epidermal growth factor receptor mutant non-small cell lung cancer
Yiqi Fuzheng Yangyin Huatan prescription
Tyrosine kinase inhibitors
Tyrosine kinase inhibitor resistance
